Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Day 1 to Week 96	STARTED	Entecavir	120
Day 1 to Week 96	STARTED	Placebo	60
Day 1 to Week 96	Received Treatment	Entecavir	120
Day 1 to Week 96	Received Treatment	Placebo	60
Day 1 to Week 96	Primary Endpoint Cohort	Entecavir	82
Day 1 to Week 96	Primary Endpoint Cohort	Placebo	41
Day 1 to Week 96	COMPLETED	Entecavir	113
Day 1 to Week 96	COMPLETED	Placebo	53
Day 1 to Week 96	NOT COMPLETED	Entecavir	7
Day 1 to Week 96	NOT COMPLETED	Placebo	7
Long-term Follow-up: Day 1-End of Study	STARTED	Entecavir	111
Long-term Follow-up: Day 1-End of Study	STARTED	Placebo	58
Long-term Follow-up: Day 1-End of Study	COMPLETED	Entecavir	92
Long-term Follow-up: Day 1-End of Study	COMPLETED	Placebo	43
Long-term Follow-up: Day 1-End of Study	NOT COMPLETED	Entecavir	19
Long-term Follow-up: Day 1-End of Study	NOT COMPLETED	Placebo	15

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01079806/flow